Industry
Biotechnology
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 10, 2024 | 9:13 am
Portfolio Pulse from Benzinga Newsdesk
May 30, 2024 | 10:29 am
Portfolio Pulse from Benzinga Newsdesk
May 13, 2024 | 11:15 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 11:12 pm
Portfolio Pulse from Benzinga Newsdesk
April 24, 2024 | 10:27 am
Portfolio Pulse from Benzinga Newsdesk
March 19, 2024 | 1:09 pm
Portfolio Pulse from Benzinga Newsdesk
March 19, 2024 | 11:16 am
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 10:39 am
Portfolio Pulse from Benzinga Newsdesk
March 18, 2024 | 10:37 am
Portfolio Pulse from Benzinga Newsdesk
March 06, 2024 | 4:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.